You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》美銀證券升翰森製藥(03692.HK)目標價至30.5元 重申「買入」評級
阿思達克 05-27 16:33
美銀證券報告指,翰森製藥(03692.HK)的阿美替尼(almonertinib)、氟馬替尼(flumatinib)、聚乙二醇洛塞那(月太)(PEG-loxenatide)、艾米替諾福韋片(tenofovir amibufenamide)分別錄得銷售額2.049億元人民幣、5,190萬元人民幣、2,000萬元人民幣和7,280萬元人民幣,按年變化分別為44.9%、57.4%、-31.0%、28.3%,按月增長分別為16.8%、34.3%、26.2%、30.8%。對於參與集中採購(VBP)的藥品,奧氮平(olanzapine)、伊馬替尼(imatinib)、培美曲塞(pemetrexed)及硼替佐米(bortezomib)在2025年3月分別錄得銷售額1,040萬元人民幣、750萬元人民幣、760萬元人民幣、70萬元人民幣,按年變化分別為-8.7%、21.1%、-22.1%、2.1%,按月變化分別為7.7%、40.7%、12.0%、35.4%。由於阿美替尼在1月至3月銷售額按年激增64.5%,該行上調其2025、2026及2027年銷售預測及總收入預測分別0.5%、1.1%及1.0%。基於強勁的藥品銷售和研發能力,重申「買入」評級,並將目標價從29.0港元上調至30.5港元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account